## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($376.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook**
- Source: ts2.tech | 20251222T170938 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) has officially joined the Nasdaq-100 Index, a move expected to boost market visibility and institutional ownership. This inclusion follows a strong year driven by the commercial success of its drug AMVUTTRA, robust financial performance in Q3 2025, and a raised revenue outlook for the year. The article also highlights strategic investments in manufacturing expansion, global approvals, and advancements in drug delivery technology, alongside analyst price targets and potential risks.

**2. Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close â€” and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251220T190932 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) shares closed near $400 on December 19, 2025, with little after-hours movement, but the upcoming U.S. market open on Monday, December 22, 2025, is poised to be significant due to the Nasdaq-100 index reconstitution, where Alnylam is being added. This inclusion is expected to drive mechanical demand from tracking funds and increase trading volume. Investors are also watching for fourth-quarter Amvuttra sales insights in early January and the company's next earnings report around February 12, 2026, alongside recent news like increased institutional ownership and manufacturing facility expansion plans.

**3. Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025**
- Source: ts2.tech | 20251220T170855 | Bullish | Relevance: 100%
- This article provides a comprehensive overview of Alnylam Pharmaceuticals (ALNY) stock as of December 20, 2025, highlighting its Nasdaq-100 index inclusion, recent financial performance driven by Amvuttra, and a new reimbursement tailwind in the U.K. It also discusses analyst forecasts, corporate finance moves, manufacturing investments, pipeline updates, and a key risk factor concerning a federal subpoena. The report emphasizes Alnylam's shift towards being a commercial-scale biotech.

**4. Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC**
- Source: MarketBeat | 20251220T140855 | Neutral | Relevance: 100%
- U.S. Capital Wealth Advisors LLC reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 47.1% in the third quarter of 2025 by selling 24,483 shares, leaving them with 27,544 shares worth $12.56 million. Despite some institutional selling and insider sales totaling over $27 million, other hedge funds increased their positions, and analysts maintain a "Moderate Buy" rating with an average target price of $477.44 for the biopharmaceutical company. The stock currently trades around $400 with a market capitalization of approximately $52.9 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 8.5% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +7.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 36.5x attractive for 126% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 44% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $53.9B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 36.5 |
| Current P/E | 82.3 |
| YoY Growth | 125.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.4% to 1.0% (+7.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-2.30), momentum weakening. RSI neutral at 41. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.00% (CS: 70) | Neutral |
| RSI_14 | 41.2 | Neutral |
| MACD Histogram | -2.30 | Bearish |
| vs SMA20 | 0.958x | Below |
| vs SMA50 | 0.915x | Below |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $407.73
- **Stop Loss:** $376.39 (7.7% risk)
- **Target:** $439.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $15,493.74
- **Portfolio %:** 15.49%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*